Skip to main content
SpringerLink
Log in

Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation

  • Letter to the Editor
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Bestetti RB, Otaviano AP, Cardinalli-Neto A, da Rocha BF, Theodoropoulos TA, Cordeiro JA (2011) Effects of B-blockers on outcome of patients with Chagas’ cardiomyopathy with chronic heart failure. Int J Cardiol 151:205–208. https://doi.org/10.1016/j.ijcard.2010.05.033

    Article  PubMed  Google Scholar 

  2. Martí-Carvajal AJ, Kwong JS (2016, 2016) Pharmacological interventions for treating heart failure in patients with Chagas cardiomyopathy. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD009077.pub3

  3. Cheymol G, Woestenborghs R, Snoeck E, Ianucci R, le Moing JP, Naditch L, Levron JC, Poirier JM (1997) Pharmacokinetic study and cardiovascular monitoring of nebivolol in normal and obese subjects. Eur J Clin Pharmacol 51:493–498. https://doi.org/10.1007/s002280050237

    Article  CAS  PubMed  Google Scholar 

  4. Keating S, Deng X, Fernandes F, Cunha-Neto E, Ribeiro AL, Adesina B, Beyer AI, Contestable P, Custer B, Busch MP, Sabino EC, NHLBI Retrovirus Epidemiology Donor Study-II (REDS-II), International Component (2015) Inflammatory and cardiac biomarkers are differentially expressed in Chagas disease. Int J Cardiol 199:451–459. https://doi.org/10.1016/j.ijcard.2015.07.040

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Gómez-Olarte S, Bolaños NI, Echeverry M et al (2019) Intermediate monocytes and cytokine production associated with severe forms of Chagas disease. Front Immunol 10:1671. https://doi.org/10.3389/fimmu.2019.01671

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Strasser SI, Mashford ML, Desmond PV (1998) Regulation of uridine diphosphate glucuronosyltransferase during the acute-phase response. J Gastroenterol Hepatol 13:88–94. https://doi.org/10.1111/j.1440-1746.1998.tb00551.x

    Article  CAS  PubMed  Google Scholar 

  7. Panaro MA, Cavallo P, Acquafredda A, Cianciulli A, Calvello R, Mitolo V (2010) Expression of UDP-glucuronosyltransferase 1A6 isoform in Caco-2 cells stimulated with lipopolysaccharide. Innate Immun 16:302–309. https://doi.org/10.1177/1753425909341909

    Article  CAS  PubMed  Google Scholar 

  8. Lévesque É, Beaulieu M, Guillemette C, Hum DW, Bélanger A (1998) Effect of interleukins on UGT2B15 and UGT2B17 steroid uridine diphosphate-glucuronosyltransferase expression and activity in the LNCaP cell line. Endocrinology 139:2375–2381. https://doi.org/10.1210/endo.139.5.6001

    Article  PubMed  Google Scholar 

  9. Vieira CP, Neves DV, Cesarino EJ, Rocha A, Poirier S, Lanchote VL (2017) An indirect stereoselective analysis of nebivolol glucuronides in plasma by LC–MS/MS: application to clinical pharmacokinetics. J Pharm Biomed Anal 144:25–30. https://doi.org/10.1016/j.jpba.2017.01.054

    Article  CAS  PubMed  Google Scholar 

  10. WHO | Sustaining the drive to overcome the global impact of neglected tropical diseases. In: WHO. http://www.who.int/neglected_diseases/9789241564540/en/. Accessed 21 Nov 2019

  11. Machavaram KK, Almond LM, Rostami-Hodjegan A, Gardner I, Jamei M, Tay S, Wong S, Joshi A, Kenny JR (2013) A physiologically based pharmacokinetic modeling approach to predict disease–drug interactions: suppression of CYP3A by IL-6. Clin Pharmacol Ther 94:260–268. https://doi.org/10.1038/clpt.2013.79

    Article  CAS  PubMed  Google Scholar 

  12. Monshouwer M, Witkamp RF, Nijmeijer SM et al (1996) Suppression of cytochrome P450- and UDP glucuronosyl transferase-dependent enzyme activities by proinflammatory cytokines and possible role of nitric oxide in primary cultures of pig hepatocytes. Toxicol Appl Pharmacol 137:237–244. https://doi.org/10.1006/taap.1996.0077

    Article  CAS  PubMed  Google Scholar 

  13. Lanchote VL, Almeida R, Barral A, Barral-Netto M, Marques MP, Moraes NV, da Silva AM, Souza TM, Suarez-Kurtz G (2015) Impact of visceral leishmaniasis and curative chemotherapy on cytochrome P450 activity in Brazilian patients. Br J Clin Pharmacol 80:1160–1168. https://doi.org/10.1111/bcp.12677

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

The authors thank CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Brazil) and CNPq (Conselho Nacional de Desenvolvimento Científico e Tecnológico) for the financial support.

Author information

Authors and Affiliations

  1. Departamento de Análises Clínicas, Toxicológicas e Bromatológicas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo, Ribeirão Preto, SP, Brazil

    Carolina Pinto Vieira, Daniel Valente Neves, Glauco Henrique Balthazar Nardotto, Evandro José Cesarino, Adriana Rocha & Vera Lucia Lanchote

  2. AMZ–Diagnósticos Médicos, Ribeirão Preto, SP, Brazil

    Ailton Marcelo Castilho Teno Zanardi

Authors
  1. Carolina Pinto Vieira
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel Valente Neves
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Glauco Henrique Balthazar Nardotto
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Evandro José Cesarino
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Adriana Rocha
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ailton Marcelo Castilho Teno Zanardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Vera Lucia Lanchote
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Carolina Pinto Vieira, Evandro José Cesarino, and Vera Lucia Lanchote contributed to the design of the study. Carolina Pinto Vieira, Daniel Valente Neves, Ailton Marcelo Castilho Teno Zanardi, and Evandro José Cesarino conducted the clinical study. Carolina Pinto Vieira, Daniel Valente Neves, Glauco Henrique Balthazar Nardotto, and Adriana Rocha undertook the analyses of the plasma concentrations of nebivolol enantiomers and their metabolites using LC-MS/MS. Carolina Pinto Vieira and Glauco Henrique Balthazar Nardotto contributed to the pharmacokinetic analyses. All authors contributed to the data interpretation, drafts, and final approval of the manuscript.

Corresponding author

Correspondence to Vera Lucia Lanchote.

Ethics declarations

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

ESM 1

(DOCX 728 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vieira, C.P., Neves, D.V., Nardotto, G.H.B. et al. Chronic Chagas disease with low plasma concentrations of IL-6 does not have a major impact on nebivolol glucuronidation. Eur J Clin Pharmacol 76, 735–737 (2020). https://doi.org/10.1007/s00228-020-02837-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-020-02837-9

Keywords

Search

Navigation